RGEN has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
RGEN has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
As of today (2024-05-16), Repligen's current share price is $174.06. Repligen's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was $7.49. Repligen's Cyclically Adjusted PS Ratio for today is 23.24.
The historical rank and industry rank for Repligen's Cyclically Adjusted PS Ratio or its related term are showing as below:
During the past years, Repligen's highest Cyclically Adjusted PS Ratio was 79.23. The lowest was 9.06. And the median was 24.59.
The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.
Repligen's adjusted revenue per share data for the three months ended in Mar. 2024 was $2.677. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $7.49 for the trailing ten years ended in Mar. 2024.
The historical data trend for Repligen's Cyclically Adjusted PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Repligen Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Cyclically Adjusted PS Ratio | Get a 7-Day Free Trial | 25.59 | 20.62 | 22.42 | 24.68 | 24.56 |
For the Medical Instruments & Supplies subindustry, Repligen's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Medical Devices & Instruments industry and Healthcare sector, Repligen's Cyclically Adjusted PS Ratio distribution charts can be found below:
* The bar in red indicates where Repligen's Cyclically Adjusted PS Ratio falls into.
Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.
Repligen's Cyclically Adjusted PS Ratio for today is calculated as
Cyclically Adjusted PS Ratio | = | Share Price | / | Cyclically Adjusted Revenue per Share |
= | 174.06 | / | 7.49 | |
= | 23.24 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Repligen's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 is calculated as:
For example, Repligen's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:
Adj_RevenuePerShare | = | Revenue per Share | / | CPI of Mar. 2024 (Change) | * | Current CPI (Mar. 2024) |
= | 2.677 | / | 131.7762 | * | 131.7762 | |
= | 2.677 |
Current CPI (Mar. 2024) = 131.7762.
Repligen Quarterly Data
Revenue per Share | CPI | Adj_RevenuePerShare | |
201406 | 0.470 | 100.560 | 0.616 |
201409 | 0.458 | 100.428 | 0.601 |
201412 | 0.486 | 99.070 | 0.646 |
201503 | 0.622 | 99.621 | 0.823 |
201506 | 0.637 | 100.684 | 0.834 |
201509 | 0.588 | 100.392 | 0.772 |
201512 | 0.641 | 99.792 | 0.846 |
201603 | 0.749 | 100.470 | 0.982 |
201606 | 0.854 | 101.688 | 1.107 |
201609 | 0.719 | 101.861 | 0.930 |
201612 | 0.745 | 101.863 | 0.964 |
201703 | 0.890 | 102.862 | 1.140 |
201706 | 0.925 | 103.349 | 1.179 |
201709 | 0.859 | 104.136 | 1.087 |
201712 | 0.936 | 104.011 | 1.186 |
201803 | 1.011 | 105.290 | 1.265 |
201806 | 1.060 | 106.317 | 1.314 |
201809 | 1.081 | 106.507 | 1.337 |
201812 | 1.117 | 105.998 | 1.389 |
201903 | 1.310 | 107.251 | 1.610 |
201906 | 1.441 | 108.070 | 1.757 |
201909 | 1.340 | 108.329 | 1.630 |
201912 | 1.310 | 108.420 | 1.592 |
202003 | 1.433 | 108.902 | 1.734 |
202006 | 1.641 | 108.767 | 1.988 |
202009 | 1.759 | 109.815 | 2.111 |
202012 | 1.952 | 109.897 | 2.341 |
202103 | 2.512 | 111.754 | 2.962 |
202106 | 2.870 | 114.631 | 3.299 |
202109 | 3.107 | 115.734 | 3.538 |
202112 | 3.225 | 117.630 | 3.613 |
202203 | 3.509 | 121.301 | 3.812 |
202206 | 3.661 | 125.017 | 3.859 |
202209 | 3.503 | 125.227 | 3.686 |
202212 | 3.275 | 125.222 | 3.446 |
202303 | 3.202 | 127.348 | 3.313 |
202306 | 2.799 | 128.729 | 2.865 |
202309 | 2.480 | 129.860 | 2.517 |
202312 | 2.790 | 129.419 | 2.841 |
202403 | 2.677 | 131.776 | 2.677 |
Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.
Thank you for viewing the detailed overview of Repligen's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Christine Gebski | officer: See Remarks | C/O REPLIGEN CORPORATION, 41 SYON ST. BLDG. 1, SUITE 100, WALTHAM MA 02453 |
Olivier Loeillot | officer: President and CCO | C/O REPLIGEN CORPORATION, 41 SEYON STREET, BUILDING 1, SUITE 100, WALTHAM MA 02453 |
Jason K Garland | officer: CFO | 10000 WEHRLE DRIVE, CLARENCE NY 14031 |
Karen A Dawes | director | 579 BELLEVUE AVE, NEWPORT RI 02840 |
Martin D Madaus | director | 290 CONCORD ROAD, BILLERICA MA 01821 |
Jon Snodgres | officer: CFO | REPLIGEN CORPORATION, 41 SEYON STREET, BUILDING #1, SUITE 100, WALTHAM MA 02435 |
Anthony Hunt | director, officer: Chief Executive Officer | 41 SEYON STREET, BUILDING 1, SUITE 100, WALTHAM MA 02452 |
Ralf Kuriyel | officer: Senior VP, R&D | 41 SEYON ST, BLDG 1, STE. 100, WALTHAM MA 02452 |
James Bylund | officer: SVP, Global Operations & IT | C/O REPLIGEN CORPORATION, 41 SYON ST. BLDG. SUITE 100, WALTHAM MA 02453 |
Konstantin Konstantinov | director | C/O CODIAK BIOSCIENCES, INC., 500 TECHNOLOGY SQUARE, 9TH FLOOR, CAMBRIDGE MA 02139 |
Manner Carrie Eglinton | director | C/O QUEST DIAGNOSTICS, 500 PLAZA DRIVE, SECAUCUS NJ 07094 |
Ryan Thomas F Jr | director | |
Nicolas Barthelemy | director | 1750 BELLA LAGUNA CT, ENCINITAS CA 92024 |
John Cox | director | C/O BIOVERATIV INC., 225 SECOND AVENUE, WALTHAM MA 02451 |
Rohin Mhatre | director | C/O REPLIGEN CORP., 41 SEYON STREET, BUILDING 1, SUITE 100, WALTHAM MA 02453 |
From GuruFocus
By Marketwired • 07-19-2023
By GuruFocus Research • 10-31-2023
By Marketwired • 11-02-2023
By sperokesalga sperokesalga • 05-31-2023
By Marketwired • 08-17-2023
By GuruFocusNews GuruFocusNews • 06-25-2022
By Marketwired • 10-17-2023
By GuruFocusNews GuruFocusNews • 07-05-2022
By GuruFocus Research • 10-31-2023
By Marketwired • 09-26-2023